We are live on ! Find out more
BLLN icon

BillionToOne Inc

105.15 USD
-5.64
5.09%
At close Updated Nov 13, 4:00 PM EST
1 day
-5.09%
5 days
-7.86%
1 month
11.34%
3 months
11.81%
6 months
16.07%
Year to date
17.76%
1 year
17.42%
5 years
-3.48%
10 years
-3.48%
 

About: BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Employees: 713

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 30%
Neutral 65%
Negative 5%
Neutral
The Motley Fool
12 hours ago
BillionToOne: 3 Key Takeaways for Long-Term Investors
BillionToOne raised 2026 revenue guidance to $460 million to $470 million. Third-quarter revenue reached $123 million, up 47% year over year.
BillionToOne: 3 Key Takeaways for Long-Term Investors
Neutral
Seeking Alpha
4 days ago
BillionToOne, Inc. (BLLN) Presents at 2026 UBS Global Healthcare Conference Transcript
BillionToOne, Inc. ( BLLN ) 2026 UBS Global Healthcare Conference November 10, 2026 2:00 PM EST Company Participants Oguzhan Atay - Co-Founder, Chairman & CEO Presentation Unknown Analyst Good afternoon. I'm Doug Schenkel with UBS, and it's my pleasure to welcome Oguzhan Atay, Co-Founder and Chief Executive Officer of BillionToOne.
BillionToOne, Inc. (BLLN) Presents at 2026 UBS Global Healthcare Conference Transcript
Neutral
Seeking Alpha
11 days ago
BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript
BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript
BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript
Neutral
Zacks Investment Research
11 days ago
BillionToOne (BLLN) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BillionToOne (BLLN) Reports Q3 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
11 days ago
BillionToOne (BLLN) Surpasses Q3 Earnings and Revenue Estimates
BillionToOne (BLLN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.
BillionToOne (BLLN) Surpasses Q3 Earnings and Revenue Estimates
Positive
MarketBeat
11 days ago
Billiontoone Q3 Earnings Call Highlights
Billiontoone NASDAQ: BLLN raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics company also reported its fifth consecutive quarter of positive GAAP operating income.
Billiontoone Q3 Earnings Call Highlights
Neutral
GlobeNewsWire
11 days ago
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026.
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
Positive
Seeking Alpha
17 days ago
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share
BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy, bypassing paternal testing and expanding to 130 genes, outpacing competitors like Natera. Oncology testing is accelerating (176% y/y growth), with Northstar Response's Medicare coverage decision by end-2026 as a key catalyst.
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share
Positive
Zacks Investment Research
18 days ago
BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growth
BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growth
Neutral
GlobeNewsWire
19 days ago
BillionToOne to Participate in Two Upcoming Investor Conferences
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences.
BillionToOne to Participate in Two Upcoming Investor Conferences
Price charts implemented using Lightweight Charts™